Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889141 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL889194 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL889178 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL889198 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL12591201 | 0.92 | DGKA (0.53) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL15693101 | 0.92 | NAAA (0.47) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL18177234 | 0.89 | DGKA (0.67) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL19399330 | 0.89 | DGKA (0.67) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL18177236 | 0.89 | DGKA (0.67) | NAAADGKAHTR2CDNM1RAD52 | |
| SCHEMBL18195611 | 0.89 | DGKA (0.67) | NAAADGKAHTR2CDNM1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | NAAA 789/4885DGKA 1291/4885HTR2C 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.